With the development of immunology and molecular biology technology and the elucidation of antibody gene structure, DNA recombination technology began to be used in the transformation of antibodies, and antibody drugs have entered the era of genetic engineering antibodies.

In the future, industrial clustering is the inevitable trend of development. Biopharmaceutical is a combinatorial process, which requires the connection of all links. It is very important to establish a clustered biopharmaceutical industry. In this way, the output efficiency of new drugs can be greatly improved, because clustering makes all aspects closely connected, and drug production can be carried out at an extremely fast speed.